{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:12:26Z","timestamp":1791637946088,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.ejphar.2015.06.015","type":"journal-article","created":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T23:18:21Z","timestamp":1434237501000},"page":"226-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":136,"special_numbering":"C","title":["Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist"],"prefix":"10.1016","volume":"761","author":[{"given":"Kiyoshi","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ubukata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiyoyuki","family":"Tsuruoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Sada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2015.06.015_bib1","unstructured":"Asoh, Y., Tsuruoka, H., Hayashi, N., Yoshida, J., Aoki, K., Homma, T., Arai, K., in preparation. Discovery of novel atropisomerism in CS-3150 as a potent non-steroidal mineralocorticoid receptor antagonist. Unpublished results."},{"key":"10.1016\/j.ejphar.2015.06.015_bib2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejphar.2015.06.015_bib3","unstructured":"Canne, B.L., Chen, J., Dalrymple, L.E., Flatt, B.T., Forsyth, T.P., Gu, X.H., Mac, M.B., Mann, L.W., Mann, G., Martin, R., Mohan, R., Murphy, B., Nyman, M.C., Stevens, W.C., Jr., Wang, T.L., Wong, Y., Wu, J.H., 2006. WO Patent no. WO2006\/012642."},{"key":"10.1016\/j.ejphar.2015.06.015_bib4","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1021\/jm500206r","article-title":"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist","volume":"57","author":"Casimiro-Garcia","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2015.06.015_bib5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejphar.2015.06.015_bib6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","article-title":"Pharmacokinetics and metabolism of [14C] eplerenone after oral administration to humans","volume":"31","author":"Cook","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2015.06.015_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/0049825021000049277","article-title":"Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats","volume":"33","author":"Cook","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejphar.2015.06.015_bib8","first-page":"691","article-title":"Sexual side-effects of spironolactones. Possible mechanisms of their anti-androgen action","volume":"5","author":"Corvol","year":"1976","journal-title":"Nouv. Presse Med."},{"key":"10.1016\/j.ejphar.2015.06.015_bib9","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.bmcl.2014.02.057","article-title":"Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series","volume":"24","author":"Cox","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2015.06.015_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0022-4731(89)90169-6","article-title":"Antialdosterones: incidence and prevention of sexual side effects","volume":"32","author":"de Gasparo","year":"1989","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.ejphar.2015.06.015_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1527-3466.2001.tb00064.x","article-title":"Eplerenone: a selective aldosterone receptor antagonist (SARA)","volume":"19","author":"Delyani","year":"2001","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.ejphar.2015.06.015_bib12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2015.06.015_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10741-005-2348-y","article-title":"The mineralocorticoid receptor and oxidative stress","volume":"10","author":"Fiebeler","year":"2005","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejphar.2015.06.015_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","article-title":"Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker","volume":"31","author":"Furumatsu","year":"2008","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2015.06.015_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"31","author":"Garthwaite","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejphar.2015.06.015_bib16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","article-title":"Aldosterone and inflammation","volume":"17","author":"Gilbert","year":"2010","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.ejphar.2015.06.015_bib17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2015.06.015_bib18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.2042-7158.1998.tb06894.x","article-title":"Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats","volume":"50","author":"Kaukonen","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.06.015_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1254\/fpj.139.241","article-title":"Revisiting the therapeutic concept of a mineralocorticoid receptor antagonist-focusing on resistant hypertension and chronic renal failure (Article in Japanese)","volume":"139","author":"Kikkawa","year":"2012","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.ejphar.2015.06.015_bib20","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1093\/ndt\/gfn301","article-title":"Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension","volume":"23","author":"Klanke","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2015.06.015_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"Lomb\u00e8s","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2015.06.015_bib22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MNH.0000000000000051","article-title":"Is there a new dawn for selective mineralocorticoid receptor antagonism?","volume":"23","author":"Luther","year":"2014","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.ejphar.2015.06.015_bib23","first-page":"1","article-title":"Renal target sites and the mechanism of action of aldosterone","volume":"9","author":"Marver","year":"1983","journal-title":"Miner. Electrolyte Metab."},{"key":"10.1016\/j.ejphar.2015.06.015_bib24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2015.06.015_bib25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/01.ASN.0000061777.67332.77","article-title":"Mineralocorticoid effects in the kidney: correlation between alphaENaC, GILZ, and Sgk-1 mRNA expression and urinary excretion of Na+ and K","volume":"14","author":"Muller","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2015.06.015_bib26","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1254\/jphs.10285FP","article-title":"SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity","volume":"115","author":"Nariai","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2015.06.015_bib27","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/FJC.0b013e3182495543","article-title":"SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats","volume":"59","author":"Nariai","year":"2012","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.06.015_bib28","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","article-title":"Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability","volume":"45","author":"Nishiyama","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2015.06.015_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2015.06.015_bib30","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1021\/jm300806c","article-title":"Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy","volume":"55","author":"Piotrowski","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2015.06.015_bib31","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctions","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2015.06.015_bib32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2015.06.015_bib33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-87-4-398","article-title":"Pathophysiology of spironolactone-induced gynecomastia","volume":"87","author":"Rose","year":"1977","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2015.06.015_bib34","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2015.06.015_bib35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1524-6175.2004.03146.x","article-title":"Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled\u00a0dose-ranging study","volume":"6","author":"Saruta","year":"2004","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ejphar.2015.06.015_bib36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2015.06.015_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejphar.2015.06.015_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0039-128X(94)00026-9","article-title":"Aldosterone biosynthesis and action in vascular cells","volume":"60","author":"Takeda","year":"1995","journal-title":"Steroids"},{"key":"10.1016\/j.ejphar.2015.06.015_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0304-3940(00)01325-2","article-title":"Expression of mineralocorticoid and glucocorticoid receptor mRNA in the human hippocampus","volume":"290","author":"Watzka","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2015.06.015_bib40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2015.06.015_bib41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MNH.0b013e3282f56854","article-title":"Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation","volume":"17","author":"Young","year":"2008","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.ejphar.2015.06.015_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2015.06.015_bib43","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1172\/JCI1915","article-title":"Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action","volume":"101","author":"Zennaro","year":"1998","journal-title":"J. Clin. Investig."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915300789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915300789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T20:58:14Z","timestamp":1537563494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299915300789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":43,"alternative-id":["S0014299915300789"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.06.015","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}